KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $286.6 million.

  • Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) rose 54.44% to $434.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $434.2 million, marking a year-over-year increase of 54.44%. This contributed to the annual value of $286.6 million for FY2024, which is 32.32% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $286.6 million for FY2024, which was up 32.32% from $216.6 million recorded in FY2023.
  • Recursion Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $286.6 million for FY2024, and its period low was $159.9 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $230.9 million, with a median of $216.6 million in 2023.
  • Data for Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY soared of 32.32% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $159.9 million in 2020, then climbed by 5.68% to $169.0 million in 2021, then grew by 12.17% to $189.6 million in 2022, then rose by 14.28% to $216.6 million in 2023, then skyrocketed by 32.32% to $286.6 million in 2024.